125 pharmaceutical companies half-yearly report forecast out, Kantai bio Q2 month-on-month growth of 100 times, drug Mingkang, Huahai Pharmaceutical...

Guide: Biomedicine and CRO industry recovery in the second quarter the fastest, the overall industry is expected to continue to rise! As the current domestic epidemic is still partially repeated and the global outbreak is not over, the pharmaceutical sector has relative certainty in the market uncertainty caused by the outbreak, which can be reflected in the performance forecast of pharmaceutical companies!----pharmaceutical sector has risen about 49% (60 stocks doubled) so far this year, second only to leisure services, its valuation is still in a high state, including vaccines and other biological products, chemical drugs are 142 times, 66 timeslong-term view, the bull market in the pharmaceutical industry still has good support, for three reasons: the domestic macroeconomic environment has undergone subtle changes, the domestic economy within the cycle-oriented;at the same time, along with the reduction of most of the domestic risk areas, the outbreak control is good, pharmaceutical enterprises after the resumption of sales, production and other pressures gradually releasedimproved from the previous quarter to 2020Q2of the 125 enterprises that have announced their first-half results, 65 pharmaceutical manufacturing companies have published their half-yearly report forecast, separating their Q1/Q2 two quarters of data, we can see that the performance of pharmaceutical enterprises related to the epidemic in the second quarter to achieve rapid growth, including the demand to enhance the larger vaccine, nucleic acid testing, API enterprises and other industriessome enterprises in other areas, although still year-on-year decline, but increased or decreased month-on-month, the overall improvement was significantthis can effectively explain that the effect of resumption of production and the epidemic levelled off, the performance of the pharmaceutical industry into a gradual recovery stagebiological drugs (non-recurrent profit and loss) can be seen from the chart above, the current 15 have published half-year forecast of biopharmaceutical enterprises, 11 enterprises Q2 compared to Q1 is an increase, the proportion of 73.3%demonstrates that biopharmaceuticals recovered faster in the second quarterThe purpose of the reform of thepayment end is mainly to optimize the industrial structure, including teng-no-generic generic high-price space to promote the development of innovative drugs, resulting in structural market conditions in the pharmaceutical industrythe innovation industry chain, which supports strong policy support, may lead the industry for a long timealso, in the state health care bureau last week in the relevant department siton of the disclosure of the news, biological products (including insulin) and traditional Chinese medicine centralized procurement has been put on the agendawith the continuous deepening of the procurement of chemical tape, the expansion of the range of collection to biological drugs is an inevitable trend, but also the continuous deepening of the reform of the payment side of medical insuranceexpects that the second half of 2020 to full year 2021, the short-term may lead to market sentiment fluctuations but not change the long-term high business climate of the pharmaceutical industry Gan Li Pharmaceuticals was established in 1998 and is a leader in the domestic insulin industry as the first enterprise in China to master the industrial production and restructuring of insulin analogue technology, in recent years, the steady growth of operating income, insulin glargine, insulin products as the main support, market share is also year-on-year growth, in 2019, to achieve operating income of 2.895 billion yuan, up 21.26% YoY; Q1 2020 due to the outbreak has been affected by some, but Q2 is gradually in a state of rapid recovery, rough estimate q2 q2, Gan Li realized revenue should be between 150 million yuan- and 187 million yuan 's overall profit for 2020 is expected to be around 1.333 billion yuan, achieving a 14% increase in net profit at present, Glyn Pharmaceuticals relies on its master of the three-generation insulin core technology, is the first domestic manufacturers with both insulin glargine and mendong insulin in addition to Tonghua Dongbao and the Federal Pharmaceutical, other domestic enterprises are relatively backward in progress, the overall market pattern is good, import substitution advantage is obvious and coincides with last week's State Health Care Administration of the relevant division of the department held a symposium revealed the news, biological products (including insulin) and traditional Chinese medicine centralized procurement work has been put on the agenda, insulin collection may become a domestic insulin alternative imported varieties of market opportunities, is expected to benefit the development of domestic insulin leading enterprises Fourth Ring Biology on July 10, Jiangsu Four Ring Biological Co., Ltd issued a half-year results forecast for 2020, the reporting period, the expected net profit of 6.2 million yuan, up 166.14% YoY but compared with the first quarter report of Four Ring Bio, learned that its Q1 net profit of 10.31 million yuan, that is, four-ring biological in the second quarter of 2020 to achieve net profit should be a loss of 3.8 million yuan, while Q1 quarter to achieve profit growth is also the main reason for the "sale of forest assets." , on June 30, Four Rings once again received an inquiry letter from the Shenzhen Stock Exchange's annual report , like the annual report inquiry received last year (the 2018 annual report inquiry), the Shenzhen Stock Exchange has also asked about its sales costs high sales costs remain the biggest problem for the four-ring edited creatures sales expenses from 2016 to 2019 were RMB105.6 million, RMB168.2 million, RMB 220 million and RMB151.3 million, in turn CRO (non-recurrent gains and losses) Although there is still a gap between China and the global level in the industrial chain, but the competitive advantage is relatively obvious, benefiting from the growth of downstream demand at home and abroad, the industry's high business climate continued in the second quarter pre-clinical CRO and CDMO orders locked in early, with high full-year results and no worries of which clinical CRO significantly recovered in Q2, the most noteworthy head of the whole industrial chain integration company and in the industrial chain at a stage with characteristics of the company in the industry the fastest recovery speed, will also be in the future development speed of the industry average drug Mingkang on the evening of July 21st, the drug Mingkang announced that the company achieved revenue of 7.231 billion yuan in the first half of 2020, up 22.68 percent year-on-year realized net profit attributable to shareholders of listed companies of RMB1.717 billion, up 62.49 percent year-on-year net profit for the April-June period was RMB1.41 billion, up 365.3% month-on-month the reasons for the change in performance, Pharma Mingkang said the company's China laboratory and contract research and development and production business (CDMO) fully resumed normal operations in the second quarter at the same time, with the rapid growth of overseas customer orders, as well as the company's capacity utilization and operating efficiency continue to improve, the company's second quarter operating income achieved strong growth 's Clinical Trial Services (CRO) and Field Management Services (SMO) businesses are also in the midst of a gradual recovery since the second quarter as a whole, the drug-mind Kant as one of the industry's leading customers, more than 70% from the United States and Europe customers but in the current outbreak of domestic light overseas heavy second quarter, the drug Mingkang can still focus on the layout of overseas customers, the number of orders has also been faster growth, capacity utilization and operating efficiency of the credit is essential, as mentioned above, the head of the whole industrial chain integration company rely on its general amount and layout is extensive, the recovery speed has been confirmed Chinese medicine (non-deductible non-recurring profit and loss) Xinbang Pharmaceuticals on the evening of July 13, Xinbang Pharmaceuticals disclosed earnings forecast, the first half of the pre-earnings of 30 million yuan - 40 million yuan, down 67.03% - 75.27% YoY but compared with the first and second quarters can be found, although affected by the new crown pneumonia and other factors, the company's first quarter operating results showed a loss, since the second quarter, production and operation can be quickly restored, the first half of the year to achieve profits, the first quarter-on-quarter growth of 430.77 percent to 507.69 percent, the first announced mid-year forecast of Chinese medicine enterprises for the reasons for the change in performance, the official announcement shows that since the second quarter, with the domestic epidemic situation gradually under control, as well as a series of national support for the resumption of production and stability of economic policy measures, production and operation can be quickly restored, the first half of the profit in recent years, the policy changes of the pharmaceutical regulatory body have brought about major changes to the policy environment in the pharmaceutical industry, with the company's sales and prices of its main products declining and operating performance falling sharply revenue growth rate for fy2017, 2018, fy2019 and first quarter of 2020 was 16.3%, 9.63%, 1.14%, and -20.22%, respectively recently, and fell into the vortex of the assets reorganization of the pharmaceutical industry, but also by the Shanghai new century into the credit watch list can be described as a disaster pharmaceuticals (non-deductible non-recurring gains and losses) Yuheng Pharmaceuticals issued a earnings forecast on the evening of July 14, and expected to make a first-half profit of 650-680 million yuan, up 179.83 percent-192.75 percent year-on-year but the growth in performance is mainly due to non-recurring gains and losses, during the reporting period confirmed the sale of 100% of Aono (China) Pharmaceutical Co., Ltd., the estimated impact on net profit of about 687 million yuan; in fact, the company's second quarter operating results improved, quarter-on-quarter improvement, but the specific figures need to wait for the mid-year statements specifically disclosed , however, the problems facing Yuheng Pharmaceuticals are not as simple as they seem the day before, Yuheng Pharmaceuticalannounced the bankruptcy reorganization of the company's controlling shareholder Yu Heng Group, at present, Yuheng Group has entered the bankruptcy reorganization proceedings caused today's "insolvent" situation is an important reason for the acquisition of Xinbang Pharmaceuticals directly related, but whether it is Xinbang Pharmaceuticals or Yuheng Pharmaceuticals, the stock price trend of the two listed companies is not as expected, Yuheng Group due to the acquisition of Xinbang Pharmaceutical stake and bear a huge financial pressure can not be alleviated, the after-effects of the merger and acquisition are all-round highlighted , yuheng pharmaceutical industry attributed to the pharmaceutical regulatory agency policy changes brought about by the changes in the pharmaceutical industry policy environment, two-vote policy, health insurance control fees and other multiple policy factors, the main product sales and prices continue to decline, the sharp decline in operating performance is its gradual decline of the important reason but perhaps, Yuheng Pharmaceuticals did not see the times and the nature of the industry may be the ultimate cause of its merger and acquisition on the road to failure, know the reason, but still do not want to make changes, which is the current generic drug generics industry is a common problem with the further development of volume procurement, there will be more types of enterprises in the future to repeat the same mistakes no doubt, now in the consistency evaluation, volume procurement, health care payment reform and so on forced the entire industry transformation and upgrading background, the market left to YuHeng Pharmaceuticals such as enterprise transformation time has been limited the advent of the era of micro-profit, only the core competitiveness of products can adapt to market development, perhaps also means that the sooner the layout of innovative drugs and high-end generic drugs, the follow-up advantages will be reflected in it timing, is the current generic drug-like enterprises first need to pay attention to the content look to the future, although the spread of the market has arrived but in recent weeks, the pharmaceutical section volatility repeatedly, many enterprises share prices and market value has been greatly affected, but on the whole, the pharmaceutical industry as the domestic more needed areas, its market value is still there, in the future the growth of the pharmaceutical industry can still be optimistic, the author believes that there are reasons for this: 1) domestic aging acceleration, pharmaceutical consumption has a new need stake is certain, the pharmaceutical industry demand is gradually gradually The exuberant, especially the pursuit of high-quality medical resources has not changed, with the increase disimportance of health, the demand for high-end products and services is also increasing; in the belt procurement, health insurance payment restructuring under the promotion of the payment side reform, promote the rapid promotion of industry concentration, leading enterprises strong Hengqiang, industry concentrated in the top of the pyramid enterprises, a healthier industrial environment can promote the long-term good development of the pharmaceutical industry; at the same time the outbreak also to a certain extent has also raised the public's attention to the pharmaceutical industry, high-end drug research and development will be accelerated investment in new health care infrastructure that complements the health care system will also boost growth in the healthcare and pharmaceutical industries combined with the above point of view, the author expects that in the second half of 2020 investors can still focus on "epidemic prevention and control", "innovation and innovation industry" "raw material syb" "Chinese medicine" four main lines future development trends to a large extent determine the starting point of these industries, of course, the main line under the layout of the head enterprises can not be ignored battle broadcast "2020 China CRO Company Rankings" selection campaign vote into the countdown more than 180 research and development CRO and CDMO companies to participate in the selection, the event visits amounted to 3.07 million plus, the cumulative number of votes 1.15 million plus as of July 22 at 18:00, Baino Pharma with 99,000 votes temporarily led the research and development CRO, the top, Kempton, Excellent Future with 59,000 plus, 51,000 plus votes in second and third place, while CDMO company popular TOP3 temporarily for Yuexing Pharmaceuticals, Sino-Peptide Biochemical, Mei Bairui all the way to watch the official, sprint stage, your enthusiasm will be the key to the campaign to reach the peak of the campaign! Quickly scan the next two-dimensional code to participate in the voting, every day for the favorite enterpriseto vote 3, after voting in accordance with the guidelines to participate in the raffle, Huawei mobile phones, tablets, high-end embroidery, professional books.. Worth 50,000 yuan, 130 plus jackpots and so on you to take! Recommended Reading: 1 Research and Development Express, Pharmaceutical Companies Lock COVID-19 Vaccine National Supply Agreement 2 Latest A shares 13 pharmaceutical companies market value of hundreds of billions! "Junshi" listed on the first day of market value of more than 251 pharmaceutical companies! 4.TOP pharmaceutical companies have signed up! The pharmaceutical industry focuses on the only annual summit of commercial operations.